Merck’s lead internal ADC candidate M9140 is currently in Phase I trials for colorectal cancer. Merck expects the SpringWorks ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Along with Erbitux and now ompenaclid, Merck is also developing M9140, a CEACAM5-targeting antibody-drug conjugate with an exatecan payload that is in an ongoing phase 1a/b study in patients with ...

Merck’s lead internal ADC candidate M9140 is currently in Phase I trials for colorectal cancer. Merck expects the SpringWorks acquisition to close in H2 2025, subject to regulatory and customary ...

RAHWAY, N.J. - Merck & Co., Inc., known as MSD outside the United States and Canada, has reached a pivotal milestone with its ...